FR2859633A1 - Immunogene synthetique pour le traitement et la prevention des abus de produits narcotiques et psychoactifs - Google Patents

Immunogene synthetique pour le traitement et la prevention des abus de produits narcotiques et psychoactifs Download PDF

Info

Publication number: FR2859633A1
Authority: FR; France
Prior art keywords: conjugate; narcotic; synthetic; polyoxydonium; immunogen
Prior art date: 2003-09-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

FR0409762A

Other languages

English (en)

French (fr)

Inventor

Konstantin Sergeevich Kosyakov

Vladimir Yurievich Plenkin

Vladimir Gennadievic Vetoshkin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PETROV ALEXANDR ALEXANDROVICH

Original Assignee

PETROV ALEXANDR ALEXANDROVICH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-15

Filing date

2004-09-15

Publication date

2005-03-18

2004-09-15 Application filed by PETROV ALEXANDR ALEXANDROVICH filed Critical PETROV ALEXANDR ALEXANDROVICH

2005-03-18 Publication of FR2859633A1 publication Critical patent/FR2859633A1/fr

Status Pending legal-status Critical Current

Links

230000002163 immunogen Effects 0.000 title claims abstract description 38
230000003533 narcotic effect Effects 0.000 title claims abstract description 17
239000000126 substance Substances 0.000 title description 14
206010012335 Dependence Diseases 0.000 title description 2
238000011321 prophylaxis Methods 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
108010074605 gamma-Globulins Proteins 0.000 claims abstract description 19
-1 aromatic propaneamines Chemical class 0.000 claims abstract description 11
150000001875 compounds Chemical class 0.000 claims abstract description 11
108010058846 Ovalbumin Proteins 0.000 claims abstract description 7
102000004169 proteins and genes Human genes 0.000 claims abstract description 7
108090000623 proteins and genes Proteins 0.000 claims abstract description 7
125000006840 diphenylmethane group Chemical class 0.000 claims abstract description 6
230000000506 psychotropic effect Effects 0.000 claims abstract description 6
IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims abstract description 5
150000003053 piperidines Chemical class 0.000 claims abstract description 5
229920000867 polyelectrolyte Polymers 0.000 claims abstract description 5
150000007656 barbituric acids Chemical class 0.000 claims abstract description 4
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 7
229940092253 ovalbumin Drugs 0.000 claims description 6
231100000757 Microbial toxin Toxicity 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
150000003384 small molecules Chemical class 0.000 claims 1
229920005617 polyoxidonium Polymers 0.000 abstract description 6
231100000614 poison Toxicity 0.000 abstract description 4
239000002574 poison Substances 0.000 abstract description 3
231100000566 intoxication Toxicity 0.000 abstract description 2
230000035987 intoxication Effects 0.000 abstract description 2
231100000699 Bacterial toxin Toxicity 0.000 abstract 1
239000000688 bacterial toxin Substances 0.000 abstract 1
150000002537 isoquinolines Chemical class 0.000 abstract 1
229960002069 diamorphine Drugs 0.000 description 24
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 24
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 22
238000003127 radioimmunoassay Methods 0.000 description 21
238000003786 synthesis reaction Methods 0.000 description 19
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 16
238000012360 testing method Methods 0.000 description 14
238000000034 method Methods 0.000 description 12
229960005181 morphine Drugs 0.000 description 12
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 12
229960003086 naltrexone Drugs 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 10
229960001797 methadone Drugs 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
239000000203 mixture Substances 0.000 description 9
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 8
229960004126 codeine Drugs 0.000 description 8
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 8
229940127240 opiate Drugs 0.000 description 8
231100000636 lethal dose Toxicity 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 5
108010008038 Synthetic Vaccines Proteins 0.000 description 5
206010013023 diphtheria Diseases 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
239000000243 solution Substances 0.000 description 5
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
229940125717 barbiturate Drugs 0.000 description 4
229940079593 drug Drugs 0.000 description 4
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 4
230000036541 health Effects 0.000 description 4
230000004727 humoral immunity Effects 0.000 description 4
229960002715 nicotine Drugs 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 3
229940025084 amphetamine Drugs 0.000 description 3
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 3
230000007969 cellular immunity Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229960003920 cocaine Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000004081 narcotic agent Substances 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
201000009032 substance abuse Diseases 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
206010002199 Anaphylactic shock Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
208000026251 Opioid-Related disease Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
208000003455 anaphylaxis Diseases 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
238000001784 detoxification Methods 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 2
AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
150000002987 phenanthrenes Chemical class 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
229950010883 phencyclidine Drugs 0.000 description 2
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
229960002695 phenobarbital Drugs 0.000 description 2
231100000572 poisoning Toxicity 0.000 description 2
230000000607 poisoning effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000000844 transformation Methods 0.000 description 2
239000002676 xenobiotic agent Substances 0.000 description 2
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
JDTUPLBMGDDPJS-UHFFFAOYSA-N 2-methoxy-2-phenylethanol Chemical compound COC(CO)C1=CC=CC=C1 JDTUPLBMGDDPJS-UHFFFAOYSA-N 0.000 description 1
SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
101001023095 Anemonia sulcata Delta-actitoxin-Avd1a Proteins 0.000 description 1
101000641989 Araneus ventricosus Kunitz-type U1-aranetoxin-Av1a Proteins 0.000 description 1
108030001720 Bontoxilysin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101001028691 Carybdea rastonii Toxin CrTX-A Proteins 0.000 description 1
101000685083 Centruroides infamatus Beta-toxin Cii1 Proteins 0.000 description 1
101000685085 Centruroides noxius Toxin Cn1 Proteins 0.000 description 1
101001028688 Chironex fleckeri Toxin CfTX-1 Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
235000015655 Crocus sativus Nutrition 0.000 description 1
244000124209 Crocus sativus Species 0.000 description 1
101000644407 Cyriopagopus schmidti U6-theraphotoxin-Hs1a Proteins 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000018526 Narcotic-Related disease Diseases 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
208000004224 Opium Dependence Diseases 0.000 description 1
101000679608 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) Cysteine rich necrotrophic effector Tox1 Proteins 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
238000013475 authorization Methods 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940053031 botulinum toxin Drugs 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
IRXBNHGNHKNOJI-UHFFFAOYSA-N butanedioyl dichloride Chemical compound ClC(=O)CCC(Cl)=O IRXBNHGNHKNOJI-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
229960001405 ergometrine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229950002454 lysergide Drugs 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
RMCDUNHIVVEEDD-UHFFFAOYSA-N methylcyclopropane Chemical compound [CH2]C1CC1 RMCDUNHIVVEEDD-UHFFFAOYSA-N 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
201000005040 opiate dependence Diseases 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000013974 saffron Nutrition 0.000 description 1
239000004248 saffron Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000001256 steam distillation Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Toxicology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

FR0409762A 2003-09-15 2004-09-15 Immunogene synthetique pour le traitement et la prevention des abus de produits narcotiques et psychoactifs Pending FR2859633A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
RU2003127705/15A RU2236257C1 (ru)	2003-09-15	2003-09-15	Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами

Publications (1)

Publication Number	Publication Date
FR2859633A1 true FR2859633A1 (fr)	2005-03-18

Family

ID=33434130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR0409762A Pending FR2859633A1 (fr)	2003-09-15	2004-09-15	Immunogene synthetique pour le traitement et la prevention des abus de produits narcotiques et psychoactifs

Country Status (5)

Country	Link
DE (1)	DE102004044666A1 (it)
EA (1)	EA006248B1 (it)
FR (1)	FR2859633A1 (it)
IT (1)	ITTO20040621A1 (it)
RU (1)	RU2236257C1 (it)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010100632A2 (en)	2009-03-06	2010-09-10	Novartis Ag	Chlamydia antigens
WO2011004263A2 (en)	2009-07-07	2011-01-13	Novartis Ag	Conserved escherichia coli immunogens
WO2011007257A1 (en)	2009-07-16	2011-01-20	Novartis Ag	Detoxified escherichia coli immunogens
WO2011008974A2 (en)	2009-07-15	2011-01-20	Novartis Ag	Rsv f protein compositions and methods for making same
WO2011048561A1 (en)	2009-10-20	2011-04-28	Novartis Ag	Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
WO2011058302A1 (en)	2009-11-10	2011-05-19	Guy's And St Thomas's Nhs Foundation Trust	Bacteremia-associated antigen from staphylococcus aureus
WO2011080595A2 (en)	2009-12-30	2011-07-07	Novartis Ag	Polysaccharide immunogens conjugated to e. coli carrier proteins
EP2368573A2 (en)	2005-11-04	2011-09-28	Novartis Vaccines and Diagnostics S.r.l.	Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP2368572A2 (en)	2005-11-04	2011-09-28	Novartis Vaccines and Diagnostics S.r.l.	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2377551A2 (en)	2005-11-04	2011-10-19	Novartis Vaccines and Diagnostics S.r.l.	Adjuvanted influenza vaccines including cytokine-inducing agents
EP2382987A1 (en)	2006-03-24	2011-11-02	Novartis Vaccines and Diagnostics GmbH	Storage of influenza vaccines without refrigeration
WO2011161551A2 (en)	2010-06-11	2011-12-29	Novartis Ag	Omv vaccines
EP2478916A1 (en)	2006-01-27	2012-07-25	Novartis Vaccines and Diagnostics GmbH	Influenza vaccines containing hemagglutinin and matrix proteins
WO2012103361A1 (en)	2011-01-26	2012-08-02	Novartis Ag	Rsv immunization regimen
EP2484377A1 (en)	2007-06-27	2012-08-08	Novartis AG	Low-additive influenza vaccines
EP2497495A2 (en)	2006-09-11	2012-09-12	Novartis AG	Making influenza virus vaccines without using eggs
EP2510947A1 (en)	2009-04-14	2012-10-17	Novartis AG	Compositions for immunising against Staphylococcus aureus
EP2514437A1 (en)	2006-07-20	2012-10-24	Novartis AG	Frozen stockpiling of influenza vaccines
WO2012158613A1 (en)	2011-05-13	2012-11-22	Novartis Ag	Pre-fusion rsv f antigens
EP2532362A1 (en)	2006-12-06	2012-12-12	Novartis AG	Vaccines including antigen from four strains of influenza virus
EP2572726A1 (en)	2007-08-01	2013-03-27	Novartis AG	Compositions comprising pneumococcal antigens
WO2013068949A1 (en)	2011-11-07	2013-05-16	Novartis Ag	Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2614835A1 (en)	2007-11-26	2013-07-17	Novartis AG	Vaccination with multiple clades of H5 influenza A virus
USH2283H1 (en)	2009-04-27	2013-09-03	Novartis Ag	Vaccines for protecting against influenza
WO2014053521A2 (en)	2012-10-02	2014-04-10	Novartis Ag	Nonlinear saccharide conjugates
EP2889042A2 (en)	2008-03-18	2015-07-01	Novartis AG	Improvements in preparation of influenza virus vaccine antigens
WO2020160199A1 (en) *	2019-01-31	2020-08-06	Siemens Healthcare Diagnostics Inc.	Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2290947C1 (ru) *	2005-10-27	2007-01-10	Александр Иванович Воронов	Способ лечения опийной наркомании
RU2526807C2 (ru) *	2012-11-28	2014-08-27	Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА"	Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997021451A1 (en) *	1995-12-14	1997-06-19	The Scripps Research Institute	Anti-cocaine vaccine
RU2112543C1 (ru) *	1996-09-26	1998-06-10	Александр Григорьевич Хоменко	Иммуномодулирующее лекарственное средство
RU2148412C1 (ru) *	1999-08-06	2000-05-10	Москаленко Екатерина Петровна	Способ получения протективного коклюшного антигена

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2073031C1 (ru) *	1990-08-06	1997-02-10	Некрасов Аркадий Васильевич	Производные поли-1,4-этиленпиперазина, обладающие иммуномодулирующей, противовирусной и антибактериальной активностями
RU2164148C1 (ru) *	2000-08-09	2001-03-20	Петров Рэм Викторович	Вакцина против вируса гриппа и способ ее получения

2003
- 2003-09-15 RU RU2003127705/15A patent/RU2236257C1/ru not_active IP Right Cessation
2004
- 2004-09-14 EA EA200401080A patent/EA006248B1/ru not_active IP Right Cessation
- 2004-09-15 FR FR0409762A patent/FR2859633A1/fr active Pending
- 2004-09-15 DE DE102004044666A patent/DE102004044666A1/de not_active Withdrawn
- 2004-09-15 IT IT000621A patent/ITTO20040621A1/it unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997021451A1 (en) *	1995-12-14	1997-06-19	The Scripps Research Institute	Anti-cocaine vaccine
RU2112543C1 (ru) *	1996-09-26	1998-06-10	Александр Григорьевич Хоменко	Иммуномодулирующее лекарственное средство
RU2148412C1 (ru) *	1999-08-06	2000-05-10	Москаленко Екатерина Петровна	Способ получения протективного коклюшного антигена

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CARRERA M R A ET AL: "SUPPRESSION OF PSYCHOACTIVE EFFECTS OF COCAINE BY ACTIVE IMMUNIZATION", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 378, no. 6558, 14 December 1995 (1995-12-14), pages 727 - 730, XP000946580, ISSN: 0028-0836 *
DAMBAEVA S V ET AL: "The effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes", CENTRAL-EUROPEAN JOURNAL OF IMMUNOLOGY 2003 POLAND, vol. 28, no. 2, 2003, pages 47 - 53, XP009054190, ISSN: 1426-3912 *
DATABASE WPI Section Ch Week 199738, Derwent World Patents Index; Class A96, AN 1997-413822, XP002346311 *
DATABASE WPI Section Ch Week 199954, Derwent World Patents Index; Class A96, AN 1999-631937, XP002346312 *
DATABASE WPI Section Ch Week 200061, Derwent World Patents Index; Class B04, AN 2000-636607, XP002346310 *
DYAKONOVA V A ET AL: "Study of interaction between the polyoxidonium immunomodulator and the human immune system cells", INTERNATIONAL IMMUNOPHARMACOLOGY 2004 NETHERLANDS, vol. 4, no. 13, 2004, pages 1615 - 1623, XP002346306, ISSN: 1567-5769 *
KOSTEN T R ET AL: "Human therapeutic cocaine vaccine: safety and immunogenicity", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 7-8, 15 January 2002 (2002-01-15), pages 1196 - 1204, XP004332992, ISSN: 0264-410X *

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3714900A1 (en)	2005-11-04	2020-09-30	Seqirus UK Limited	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2368573A2 (en)	2005-11-04	2011-09-28	Novartis Vaccines and Diagnostics S.r.l.	Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP2368572A2 (en)	2005-11-04	2011-09-28	Novartis Vaccines and Diagnostics S.r.l.	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2377551A2 (en)	2005-11-04	2011-10-19	Novartis Vaccines and Diagnostics S.r.l.	Adjuvanted influenza vaccines including cytokine-inducing agents
EP2478916A1 (en)	2006-01-27	2012-07-25	Novartis Vaccines and Diagnostics GmbH	Influenza vaccines containing hemagglutinin and matrix proteins
EP3753574A1 (en)	2006-01-27	2020-12-23	Seqirus UK Limited	Influenza vaccines containing hemagglutinin and matrix proteins
EP2382987A1 (en)	2006-03-24	2011-11-02	Novartis Vaccines and Diagnostics GmbH	Storage of influenza vaccines without refrigeration
EP2514437A1 (en)	2006-07-20	2012-10-24	Novartis AG	Frozen stockpiling of influenza vaccines
EP3456348A1 (en)	2006-09-11	2019-03-20	Seqirus UK Limited	Making influenza virus vaccines without using eggs
EP2497495A2 (en)	2006-09-11	2012-09-12	Novartis AG	Making influenza virus vaccines without using eggs
EP2679240A1 (en)	2006-12-06	2014-01-01	Novartis AG	Vaccines including antigen from four strains of influenza virus
EP2532362A1 (en)	2006-12-06	2012-12-12	Novartis AG	Vaccines including antigen from four strains of influenza virus
EP2484377A1 (en)	2007-06-27	2012-08-08	Novartis AG	Low-additive influenza vaccines
EP2572726A1 (en)	2007-08-01	2013-03-27	Novartis AG	Compositions comprising pneumococcal antigens
EP2614835A1 (en)	2007-11-26	2013-07-17	Novartis AG	Vaccination with multiple clades of H5 influenza A virus
EP3459563A1 (en)	2008-03-18	2019-03-27	Seqirus UK Limited	Improvements in preparation of influenza virus vaccine antigens
EP2889042A2 (en)	2008-03-18	2015-07-01	Novartis AG	Improvements in preparation of influenza virus vaccine antigens
EP3549602A1 (en)	2009-03-06	2019-10-09	GlaxoSmithKline Biologicals S.A.	Chlamydia antigens
WO2010100632A2 (en)	2009-03-06	2010-09-10	Novartis Ag	Chlamydia antigens
EP3263128A2 (en)	2009-04-14	2018-01-03	GlaxoSmithKline Biologicals S.A.	Compositions for immunising against staphylococcus aureus
EP2510947A1 (en)	2009-04-14	2012-10-17	Novartis AG	Compositions for immunising against Staphylococcus aureus
USH2284H1 (en)	2009-04-27	2013-09-03	Novartis Ag	Vaccines for protecting against influenza
USH2283H1 (en)	2009-04-27	2013-09-03	Novartis Ag	Vaccines for protecting against influenza
WO2011004263A2 (en)	2009-07-07	2011-01-13	Novartis Ag	Conserved escherichia coli immunogens
EP3988115A2 (en)	2009-07-15	2022-04-27	GlaxoSmithKline Biologicals S.A.	Rsv f protein compositions and methods for making same
EP3178490A2 (en)	2009-07-15	2017-06-14	GlaxoSmithKline Biologicals S.A.	Rsv f protein compositions and methods for making same
EP4183412A1 (en)	2009-07-15	2023-05-24	GlaxoSmithKline Biologicals S.A.	Rsv f protein compositions and methods for making same
EP4218800A1 (en)	2009-07-15	2023-08-02	GlaxoSmithKline Biologicals S.A.	Rsv f protein compositions and methods for making same
EP4218799A1 (en)	2009-07-15	2023-08-02	GlaxoSmithKline Biologicals S.A.	Rsv f protein compositions and methods for making same
WO2011008974A2 (en)	2009-07-15	2011-01-20	Novartis Ag	Rsv f protein compositions and methods for making same
EP2837386A1 (en)	2009-07-16	2015-02-18	Novartis AG	Detoxified Escherichia coli immunogens
WO2011007257A1 (en)	2009-07-16	2011-01-20	Novartis Ag	Detoxified escherichia coli immunogens
WO2011048561A1 (en)	2009-10-20	2011-04-28	Novartis Ag	Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
WO2011058302A1 (en)	2009-11-10	2011-05-19	Guy's And St Thomas's Nhs Foundation Trust	Bacteremia-associated antigen from staphylococcus aureus
WO2011080595A2 (en)	2009-12-30	2011-07-07	Novartis Ag	Polysaccharide immunogens conjugated to e. coli carrier proteins
WO2011161551A2 (en)	2010-06-11	2011-12-29	Novartis Ag	Omv vaccines
EP3399021A1 (en)	2010-06-11	2018-11-07	GlaxoSmithKline Biologicals S.A.	Omv vaccines
WO2012103361A1 (en)	2011-01-26	2012-08-02	Novartis Ag	Rsv immunization regimen
EP3527224A1 (en)	2011-01-26	2019-08-21	GlaxoSmithKline Biologicals S.A.	Rsv immunization regimen
EP4159232A1 (en)	2011-01-26	2023-04-05	GlaxoSmithKline Biologicals S.A.	Rsv immunization regimen
EP4144368A1 (en)	2011-01-26	2023-03-08	GlaxoSmithKline Biologicals S.A.	Rsv immunization regimen
EP3275892A2 (en)	2011-05-13	2018-01-31	GlaxoSmithKline Biologicals S.A.	Pre-fusion rsv f antigens
WO2012158613A1 (en)	2011-05-13	2012-11-22	Novartis Ag	Pre-fusion rsv f antigens
WO2013068949A1 (en)	2011-11-07	2013-05-16	Novartis Ag	Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2014053521A2 (en)	2012-10-02	2014-04-10	Novartis Ag	Nonlinear saccharide conjugates
JP2022519534A (ja) *	2019-01-31	2022-03-24	シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド	抗ナロキソンおよび抗ナルトレキソンモノクローナル抗体ならびにその作製方法および使用方法
US20220049018A1 (en) *	2019-01-31	2022-02-17	Siemens Healthcare Diagnostics Inc.	Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
CN113424060A (zh) *	2019-01-31	2021-09-21	美国西门子医学诊断股份有限公司	抗纳洛酮和抗纳曲酮单克隆抗体及其生产和使用方法
WO2020160199A1 (en) *	2019-01-31	2020-08-06	Siemens Healthcare Diagnostics Inc.	Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
JP2024045330A (ja) *	2019-01-31	2024-04-02	シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド	抗ナロキソンおよび抗ナルトレキソンモノクローナル抗体ならびにその作製方法および使用方法
US12404346B2 (en)	2019-01-31	2025-09-02	Siemens Healthcare Diagnostics Inc.	Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
JP2025139595A (ja) *	2019-01-31	2025-09-26	シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド	抗ナロキソンおよび抗ナルトレキソンモノクローナル抗体ならびにその作製方法および使用方法

Also Published As

Publication number	Publication date
ITTO20040621A1 (it)	2004-12-15
RU2236257C1 (ru)	2004-09-20
EA200401080A1 (ru)	2005-04-28
EA006248B1 (ru)	2005-10-27
DE102004044666A1 (de)	2005-04-28

Publication	Publication Date	Title
FR2859633A1 (fr)	2005-03-18	Immunogene synthetique pour le traitement et la prevention des abus de produits narcotiques et psychoactifs
US6699474B1 (en)	2004-03-02	Vaccine and immunserum against drugs of abuse
DE69931377T2 (de)	2007-05-10	Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
Schwartz	1969	Chemical aspects of penicillin allergy
FR2598622A1 (fr)	1987-11-20	Adjuvants immunologiques pour vaccins polysaccharidiques
US8357375B2 (en)	2013-01-22	Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction
RU2532911C2 (ru)	2014-11-20	Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
HUP0104365A2 (hu)	2002-04-29	Nikotinfüggőség kezelésére és megelőzésére alkalmas haptén-hordozó konjugátumok, azokat tartalmazó vakcinák és gyógyászati készítmények a kojugátumokra válaszként termelődő antitest és alkalmazásuk
FR2513125A1 (fr)	1983-03-25	Medicament curatif du deficit immunitaire
CA2067205C (en)	2009-10-27	Vaccine and immune serum against drugs of abuse
US20100015172A1 (en)	2010-01-21	Method to reduce the physiologic effects of drugs on mammals
DE69630682T2 (de)	2004-09-16	Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
EP0001197B1 (fr)	1981-11-04	Produits de couplage de la cytidine-diphosphocholine et de composés aminés, procédé d'obtention et application pharmaceutique et analytique
CN102002049B (zh)	2013-01-02	一种抗原及其制备方法与应用
RU2526807C2 (ru)	2014-08-27	Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ
JPS62228023A (ja)	1987-10-06	免疫学的増幅因子と関連組成物
RU2635517C1 (ru)	2017-11-13	Синтетический иммуноген для защиты и лечения от зависимости от психоактивных веществ
RU2643329C1 (ru)	2018-01-31	Синтетический иммуноген для защиты и лечения от зависимости от психоактивных веществ
JPH09505563A (ja)	1997-06-03	抗アレルギー治療に有効な化合物
JP2001506994A (ja)	2001-05-29	免疫グロブリン受容体相互作用の阻害剤を含んでいる医薬組成物
RU2548802C1 (ru)	2015-04-20	Иммуноген для лечения и профилактики зависимости от опиатов
RU2259847C1 (ru)	2005-09-10	Вакцина против гипертонии
De Weck	1968	Drug Allergy [Abridged] The Formation of Penicillin Antigens
EP0316212B1 (fr)	1995-03-08	Application de nitrophényles ou d'anticorps anti-nitrophényles à la modification de l'interaction entre des cellules sensibles d'un hôte et un agent pathogene
EP0215081A1 (fr)	1987-03-25	Preparations d'immunoglobulines presentant des titres eleves en anticorps bloquants